

International Journal of Drug Development & Research | April-June 2010 | Vol. 2 | Issue 2 | ISSN 0975-9344 Available online http://www.ijddr.com ©2010 IJDDR

# Full Length Research Paper

# DESIGN AND SYNTHESIS OF 4-[2'-(5'- NITRO)] IMIDAZOLYL BENZOYL (N-METHYL) AMINO ACIDS AND PEPTIDES

## \*PARAMITA DAS AND M.HIMAJA

#### DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, MORADABAD INSTITUTE OF TECHNOLOGY MORADABAD (U.P)-244001 NGSM INSTITUTE OF PHARMACEUTICAL SCIENCES, NANTHOOR, MANGALORE-575005.

# ABSTRACT

In the past two decades, a wide variety of bioactive peptides have been discovered. Condensation of heterocyclic moieties viz nicotinic acid, thiazole coumarin, quinolin, furan, imidazole etc. with amino acids and peptides resulted in compounds with potent biological activities. Many of the heterocyclic found to exhibit antifungal, antibacterial, cytotoxic, antineoplastic, insectisidal, antiinflammatory, anthelmintic, tyrosinase inhibitory and melanin production inhibitory

activities. Metronidazole, serconidazole, flucanazole are well known marketed drugs. Introduction of D-amino acids and N-methylation of amino acids like tyrosine, valine, alanine etc enhanced antimicrobial activity. Hence an attempt is made towards the synthesis of 5-nitroimidazolyl-benzoic acid derivative of N-methylamino acids and peptide using solution phase technique of peptide synthesis. The method includes the introduction of tert-butyloxy carboxyl group (Boc) to amino acids to protect the amino group forming Boc-amino acids .The protection of carboxyl group was done by converting the amino acids into corresponding methyl ester. The protected amino acids were coupled using diisopropylcarbodimide and triethylamine to get protected dipeptides. N-methylation was done by treating with methyl iodide and sodium hydride. The ester group was then removed by lithium hydroxide. The Boc(N-methyl)dipetide were coupled to amino acids or Boc(Nmethyl)dipeptide were coupled to 4-[2-(5-nitro)imidazoly]benzoic acids.

Keywords: Imidazole, N-Methylation, Antibacterial, Antifungal, Anthelmintic

# INTRODUCTION

4-[2'-(5'-NITRO)IMIDAZOLYL] BENZOYL(N-METHYL) AMINO ACIDS AND PEPTIDES were prepared by coupling 4-[2'-(5'-nitro) imidazoly1] benzoic acids with corresponding N-methylated amino acids methyl ester hydrochloride or dipeptide methyl ester. Representative compounds have been characterized for antifungal and anthelmintic activities.

**Correspondence email ID:** e-mail:paramitadas04@gmail.com Imidazole or imidazoline, earlier called glyoxalin was prepared from glyoxal and ammonia. Imidazole nucleus, found in essential amino acids, exhibit potent antiprotozal, antifungal and antibacterial<sup>[1]</sup> activities besides acting as adrenergic and anthelmintic agents. In continuation of earlier work<sup>[2]</sup> on the synthesis of a new series of 5nitromidazole of amino acids and peptides, the synthesis of 4-[2'-(5'-NITRO)IMIDAZOLYL] BENZOLYN(N-METHYL) AMINO ACIDS AND PEPTIDES along with their anti microbial and anthelmintic activities.

Imidazole was nitrated with nitrating mixture [Conc.H<sub>2</sub>SO<sub>4</sub>] and HNO<sub>3</sub> (1:1)] 5to get nitroimidazole. P-amino benzoic acid was diazotized with sodium nitrite and dilutes hydrochloric acid at 0° C. The resulting diazonium salt was stirred with 5-nitroimidazole in the presence of an aqueous solution of cupric chloride for 4hrs at room temperature to get 4-[2'-(5'-NITRO)IMIDAZOLYL]BENZOIC ACID (2).Amino acids  $(2a_1-a_5)$  were converted into the corresponding methyl ester hydrochloride  $(3b_1-b_5)$ using thionyl chloride and methanol. N-methylation was done by treating with methyl iodide and sodium hydride by following methods of Benoition<sup>[3]</sup> and Jullie<sup>[4]</sup> to get Boc-(N-Me) amino acids methyl ester. The Boc group of N-methylated amino acids methyl ester (4c<sub>1</sub>-c<sub>5</sub>) was removed by trifluroacetic acid. The required dipeptides(10h<sub>1</sub>-h<sub>5</sub>) were prepared by coupling Boc N-methylated-amino acid with the respective amino acid ester hydrochloride using di- isopropy1carbodiimide and N-methyl morpholine as per Bodanszky's<sup>[5]</sup> procedure. The Nmethylated amino acid methyl ester were coupled with 4-[2'-(5'-NITRO)IMIDAZOLYL|]BENZOIC ACID using isopropy1-di carbodiimide, N-methyl morpholine and triethylamine to obtain the title compounds which were characterized on the basis of spectral data.



#### Scheme 1

 $\begin{array}{l} R = side \ chain \ at \ (a) \ Val(7e_1), \ Phe(7e_2), \ Tyr(7e_3), \ Thr(7e_4), \ Leu(7e_5) \\ R = side \ chain \ at \ (b) \ Val(8f_1), \ Phe(7e_4), \ Tyr(8f_3), \ Thr(8f_4), \ Leu(8f_5) \\ R, \ R1 = side \ chain \ at \ (c) \ Phe-Pro \ (10h_1), \ Thr-Phe(10h_2), \ Leu-Tyr(10h_3) \end{array}$ 

#### MATERIAL AND METHOD

Melting points were recorded in open capillary tubes. Purity of compound was confirmed by TLC on silica gel-G using chloroform: glacial acetic acid: water (3:2:5) as solvent and iodine vapor as visualizing agent. The IR spectra were recorded on JASCO FTIR 300 SPECTROMETER and <sup>1</sup>HNMR spectra were recorded on BRUCKER AC NMR spectra were recorded on BRUCKER AC NMR spectrometer (300MHz) using CDCL<sub>3</sub> as internal standard. FAB MASS spectra were recorded on a Joel Sx 102/DA 6000 mass spectrometer using xenon as the carrier gas.

#### **GENERAL PROCEDURE**

#### **Preparation of Nitroimidazole:**

Concentrated sulphuric acid (53ml) and fuming nitric acid (38ml) were taken in a 250 ml round bottom flask and imidazole (75g, 1.1 moles) was added slowly in small portions with regular shaking. The mixture was refluxed shaking for 30 mins, allowed to cool and cautiously poured into 500ml of water. The precipitated nitroimidazole was filtered and washed with water.

# Preparation of 4-[2'-(5'-nitro)imidazoly]benzoic acid (2):

A mixture of p-amino benzoic acid (34.25 gm, 250 m mol), dilute hydrochloric acid (120ml) and water (150 ml) was heated to get a clear solution. The solution was cooled to  $0^{\circ}-5^{\circ}$ C and diazotized by the addition of 30% of sodium nitrite solution (48ml). To the above diazonium salt solutions, dilute hydrochloric acid (100ml), nitroimidazole (250mmol) and aqueous cupric chloride solution (25% ml) were added with stirring. The mixture was shakes for 6 hrs and kept overnight in the refrigerator. The separated solid was filtered, washed with water and recrystalized with acetone.

Preparation of Amino acid methyl ester hydrochlorides (3b<sub>1</sub>-b<sub>5</sub>):

The methyl ester hydrochlorides of all five amino (valine, threonine, leucine, tyrosine, phenylalanine) were prepared separately by slowly adding 20 mmol of corresponding amino acid to a mixture was irradiated in microwave (Model M 1739 N) at 180W for 15 minutes to give a pasty mass of methyl ester hydrochloride which was triturated with ether at 0° C to remove excess of dimethyl sulphite. The resulting solid was recrystalised with a mixture of methanol and diethyl ether (1:1)

**Preparation of the Boc-Amino acid methyl ester:** To a solution of amino methyl ester hydrochloride (2.2 mmol) in chloroform (20ml) was added triethlamine (4 mmol) followed by (Boc<sub>2</sub>)O (4.5 ml, 1.81 m mol) and ether (15 ml). The mixture was stirred for 2 hours at room temperature and washed with 10% NaHCO<sub>3</sub> (2 x 10ml). The organic layer was separated. Dried and concentrated to get Bocamino acid methyl ester which was recrystalized, with n-hexane at-  $15^{\circ}$  C. Using their procedure, following Boc-amino acid methyl ester were prepared:

# Preparation of Boc-(N-Me) Amino acid methyl ester (4c<sub>1</sub>-c<sub>5</sub>):

Corresponding Boc-amino acid methyl ester (5.5 mmol) was dissolved in dimethyl formamide (30ml), and sodium hydride (0.75 gm, 16.5 mmol) was added at room temperature followed by methyl iodide (6.3 gm, 44 mmol). To the above mixture 15 ml of ether was added and shaked well for 4 hrs. The solution was washed with saturated NH<sub>4</sub>CI (20 ml) followed by 20% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (20 ml) and saturated NaCl (20 ml). The ether layer was separated, dried with anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give the title compound as viscous oil.

## **Preparation of the Dipeptides (9g<sub>1</sub>-g<sub>5</sub>):**

Amino acid methyl ester hydrochloride (10mmol) was dissolved in chloroform (20ml) and Nmethylmorpholine (1.3ml) was added and the

mixture was stirred for 15 minutes. Boc (N-Me) amino acid (10 mmol) in chloroform (20 ml) and diisopropyl carbamide (10 mmol) was added to the above mixture with stirring. After 24 hours, the reaction mixture was shaken with chloroform (30ml). The chloroform layer was separated and washed with 5% NaHCO<sub>3</sub> (20ml) followed by saturated NaCI (20 ml) solution and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated in vacuum to get dipeptide.

Preparation of 4[2'-(5'-nitro) imidazolyl]benzoyl (N-Me) amino acid and peptide methyl ester (7e<sub>1</sub>e<sub>5</sub>, 8f<sub>1</sub>-f<sub>5</sub>, 10h<sub>1</sub>-h<sub>3</sub>):

A mixture of amino acid methyl ester (7.0 mmol) tetrahvdrofuran (20)ml). 4-[2'-(5'nitro)imidazolyl]benzoic acid (1.631 gm, 7.0 m mol), di-isopropyl carbodiimide and triethylamine (208ml) was stirred at room temperature for 24 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was dissolved in chloroform, washed with 10% NaHCO<sub>3</sub> (10ml) followed by 5% hydrochloric acid (10ml), dried anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated under vacuum to get the title compound. The crude product was recrystalized from CHCI<sub>3</sub> and n-hexane. The data are given in the following table:-

Sl. No	Compound No.	Physical State	Molecular Formula	Molecular Weight	M.P.°C	% Yield
1.	7e <sub>1</sub>	Reddish Brown Solid	$C_{15}O_5N_4H_{16}$	332	68-70 C	74.53
2.	7e <sub>2</sub>	Reddish Brown Solid	$C_{19}O_5N_4H_{16}$	380	93-95 C	95.5
3.	7e <sub>3</sub>	Yellow Crystals	$C_{19}O_6N_4H_{16}$	396	92-95 C	27.41
4.	7e <sub>4</sub>	Brown Crystals	$C_{14}O_6N_4H_{14}$	334	80-82 C	37.94
5.	7e <sub>5</sub>	Yellow Solid	$C_{16}O_5N_4H_{18}$	346	61-64 C	23.17
6.	$8f_1$	Yellow Brown Solid	$C_{16}O_5N_4H_{18}$	346	118-120 C	51.23
7.	$7e_4$	Brown Semi-solid	$C_{20}O_5N_4H_{18}$	394	_	50.73
8.	8f <sub>3</sub>	Brown Semi-solid	$C_{20}O_6N_4H_{18}$	410	_	37.94
9.	$8f_4$	Brown Semi-solid	$C_{15}O_6N_4H_{16}$	348	_	33.33
10.	8f <sub>5</sub>	Brown Semi-solid	$C_{17}O_5N_4H_{20}$	360	_	43.95
11.	$10h_1$	Yellow viscous liquid	$C_{25}O_6N_5H_{25}$	491	_	27.35
12.	10h <sub>2</sub>	Brown Semi-solid	$C_{24}O_7N_5H_{25}$	585	_	18.86
13.	10h <sub>3</sub>	Reddish Brown semisolid	$C_{26}O_7N_5H_{29}$	523	_	43.95

Table 1.	Physical	and analy	vtical data	of com	pounds	prepared:
I GOIC I.	I II , DICUI	and and	, nour autu	01 00111	poundo	preparea.

#### SPECTRAL RESULTS

**1)7e<sub>5</sub>:** <sup>1</sup>HNMR (300 MHz CDCI<sub>3</sub>)  $\delta$  in PPM: 7.9 (1H,m,- NH), 7.7 (1H, m, Aromatic-H), 7.4 (2H, m, Aromatic-H), 6.8 (2H, m, Aromatic-H), 4.9 (1H, m, ar-H), 3.8 (1H, s, COCH<sub>3</sub>), 1.4 (2H, d,  $\beta$ -CH<sub>2</sub> of Leucine ), 1.2 (1H, m,  $\beta$  -H), 0.95 (6H, CH<sub>3</sub> group of Leucine)

IR (CHCI<sub>3</sub>) in cm<sup>-1</sup>: 3305.5 (Aromatic C-H stretching), 2930.9 (Aliphatic C-H stretching), 1707.3 (C=O (ester) stretching), 1608 (C=O (amide) stretching), 1545.7 (N-H bending), 1509.2 (C-H bending)

**2)7e<sub>1</sub>:** 7.7 (2H, d, Aromatic-H), 7.6 (2H, d, aromatic-H), 7.14 (1H, s, Aromatic-H), 6.3 (1H, br.s, NH<sub>2</sub>), 4.6 (1H, m  $\alpha$ -H), 3.8 (3H, s,-COCH<sub>3</sub>), 1.2 (1H, m,  $\beta$ -h), 0.85 (6h, CH<sub>3</sub> group of Valine)

IR (CHCI<sub>3</sub>) in cm-<sup>1</sup>: 3292.1 (Aromatic C-H Stretching), 2931.1 (aliphatic C-H stretching), 1701.5 (C=O (ester) stretching), 1628.9 (C=O (amide) stretching), 1543.6 (N-H bending), 1487.3 (C-H bending)

**3) 8f**<sub>5</sub> : <sup>1</sup>H NMR (300 MHz CDCI<sub>3</sub>) δ in PPM: 7.9 (1H,m,- NH), 7.7 (1H, m, Aromatic-H), 7.4 (2H, m, Aromatic-H), 6.9 (2H m, Aromatic-H), 4.8 (1H, m,

 $\alpha$ -H), 3.8 (1H, s, COCH<sub>3</sub>), 2.9 (1H, s, -N-CH<sub>3</sub>), 1.4 (2H, β-CH<sub>2</sub> of Leucine), 1.2 (1H, m, γ-H), 0.95 (6H,d, CH<sub>3</sub> group of Leucine)

IR (CHCI<sub>3</sub>) in cm<sup>-1</sup> : 3305.5 (Aromatic C-H stretching), 2930.9 (Aliphatic C-H stretching), 2870.1 (Aliphatic C-H Stretching), 1707.3 (C=O (ester) stretching), 1609 (C=O (amide) stretching), 1544.7 (N-H bending), 1508.2 (C-H bending)

**Mass in m/z:** 375, 352, 313, 285, 253, 220, 171, 146, 121, 102 and 100.

4) 8f<sub>1</sub> : (300 MHz CDCI<sub>3</sub> )  $\delta$  in PPM: 7.7 (2H, d, Aromatic-H), 7.6 (2H, d, aromatic-H), 7.15 (1H, s, Aromatic-H), 6.2 (1H, br.s, NH<sub>2</sub>), 4.6 (1H, m  $\alpha$ -H), 308 (3H, s,-COCH<sub>3</sub> ) 2.9 (3H,s , -NCH<sub>3</sub>) ,1.2 (1h, m,  $\beta$ -H), 0.85 (6H, CH<sub>3</sub> group of Valine)

IR (CHCI<sub>3</sub>) in cm<sup>-1</sup> : 3292.1 (Aromatic C-H Stretching), 2931.1 (aliphatic C-H stretching), 2855.4 (aliphatic C-H stretching), 1701.5 (C=O (ester) stretching), 1628.9 (C=O (amide) stretching), 1543.6 (N-H bending), 1487.3 (C-H bending)

 Mass
 in
 m/z:

 361,336,320,306,271,250,238,225,207,190,158,125,
 98and 96.

#### ANTIMICROBIAL ACTIVITY

The synthesized compounds were screened for antibacterial and antifungal activities. The antibacterial and antifungal activity were studied in a concentration of  $50\mu g/ml$  against four bacterial (*S.aureus, B.subtilis, P.aeruginosa* and *E-coli*) and one fungus (*C.albicans*) by disc diffusion method. Solution of benzil penicillin and fluconazole were used as standard antibacterial and antifungal drugs respectively solvents used for both standards.

The culture media used were nutrient agar and Sabouraud's<sup>[6]</sup> medium for bacteria and fungus respectively. All compounds have shown promising antibacterial and antifungal activity. However, the activities  $8f_{1},8f_{2},8f_{5}$  and  $10h_{1},10h_{2},10h_{3}$  of compounds  $10h_{1},10h_{2},10h_{3}$  were more pronounced in comparison to compounds  $8f_{1},8f_{2},8f_{5}$  and found to be equivalent to 90% of standards drugs benzyl penicillin and fluconazole.

SL.No	Diameter of Zone of inhibition (in mm)							
	Compound No	B.Sub	S.aur	E.coli	P.aer	C.alb		
1	31	10	10	11	9	12		
2	32	9		: <b>-</b> :	9	18		
3	33	10	9	9	10	9		
4	34	10	10	11	9	10		
5	35	10	8 <del></del>	2.00	9	8		
6	36	16	-	12	-	21		
7	37	15	18	11	10	20		
8	38	10	21	13		18		
9	39	11	16	16	15	19		
10	40	12	24	13	1.7	20		
11	41	18	20	15	16	16		
12	42	19	21	16	16	17		
13	43	18	15	14	13	16		
14	Benzil pencillin	16	25	16	16			
15	Fuconzole		-	-	19 <b>4</b>	20		

#### Table 2: Results of Antimicrobial Activity

Int.J.Drug Dev. & Res., April-June 2010, 2(2):364-370

SI.	Compound		Pres	ence/A	bsence	of grov	vth	
No	No			Candi	da albi	cans		
1	Dilutions	I	11	ш	IV	v	VI	VII
1	31	-	+	+	+	+	+	+
2	32	-	-	+	+	+	+	+
3	33	-	-	-	+	+	+	+
4	34	-	+	+	+	+	+	+
5	35	-	-	+	+	+	+	+
6	36	-	-	+	+	+	+	+
7	37	-	+	+	+	+	+	+
8	38	-	+	+	+	+	+	+
9	39	-	+	+	+	+	+	+
10	40	-	+	+	+	+	+	+
11	41	-	+	+	+	+	+	+
12	42	-	-	+	+	+	+	+
13	43	-	+	+	+	+	+	+
14	Fluconazole	-	-	-	-	-	-	-

#### Table 3: Minimum Inhibitory Concentration for Antifungal Activity

'+' indicates presence of growth, '-' indicates absence of growth

# ANTHELMINTIC ACTIVITY

All compounds were tested for anthelminitic activity by Garg's<sup>[7]</sup> method using Mebendazole as standard drug. Anthelmintic activity studies were carried out against *Eudrilus eugeniea*. The study revealed that the compounds  $8f_1$ ,  $8f_2$ ,  $8f_5$  have moderate to significant activities and their efficacy is enough to develop as clinically useful agents. The dipeptide compound 10h1, 10h2, 10h3 showed 95% activity when compared with standard drug and hence requires special attention for developing as therapeutic agents.

Sl.No	Compound No	Conc. of the compound (mg)	Mean paralying time (min) <u>+</u> S.E N.E		Mean death time (min) <u>+</u> S.E	
1	Control	a-				
2	Mebendazole	100	6.00	<u>+</u> 0.34	7.40	<u>+</u> 0.24
3	36	100	6.90	<u>+</u> 0.31	7.35	<u>+</u> 0.47
4	37	100	6.12	<u>+</u> 0.35	7.34	<u>+</u> 0.43
5	38	100	6.10	<u>+</u> 0.51	6.90	<u>+</u> 0.33
6	39	100	7.04	<u>+</u> 0.32	8.29	<u>+</u> 0.24
7	40	100	6.10	<u>+</u> 0.31	7.40	<u>+</u> 0.37
8	41	100	7.05	<u>+</u> 0.29	7.90	<u>+</u> 0.37
9	42	100	6.00	<u>+</u> 0.25	7.45	<u>+</u> 0.26
10	43	100	6.05	<u>+</u> 0.28	7.95	<u>+</u> 0.32

**Table 4:** Results of Anthelmintic Activity:

S.E represent Standard Error and N.E. indicates No Effect

#### DISCUSSION AND CONCLUSION

All the synthesized compounds were subjected to antimicrobial activity and anthelmintic activity. Nmethylated analog has shown significant anti bacterial activity. The dipeptides showed good activity against gram positive as well as gram negative *E.coli* and *P.aereginosa*. All the compounds showed potent antifungal activity against *C.albicans*.

#### ACKNOWLEDGEMENT

The authors are thankful to Nitte Education Trust, Mangalore for providing all the facilities and Heads of RSIC, CDRI, Lucknow and Punjab University, Chandigarh for the analytical and spectral data.

## REFERENCE

- SL Belagali and M Himaja. Synthesis and Biological Activity of Pyridine -3- carboxyl amino acids and peptides. Indian j. heterocyclic chem. 1998; 8:11
- M.Himaja, Rajiv and M.V Ramana,. Indian J. Heterocyclic chem., 12(2002), 121
- N.L, Benoiton, D. Akyusekli and F.M.N Chen, International J Pep Protein Res.45 (1995), 466
- C.M.Scott, R Joshi, D.V.Mayhew, J.P.Amy and M.M.Joullie, J Org Chem.59 (1994), 592
- M. Bodanszky and A. Bodanszky, Practice of peptide synthesis, New Springer-Verlag Publishers, 59 (1984), 591.
- Indian Pharmacopoeia 1996 Vol II appendex 9.1 A105 -107
- L.C. Garg, C.K. Atal., Indian J Pharmcol, 31 (1969), 104.

Article History:-----Date of Submission: 23-02-10 Date of Acceptance: 24-04-10 Conflict of Interest: NIL Source of Support: NONE